# OnCo record nct02343042 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02343042/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02343042", "NCT02343042" ;
  schema:name "Selinexor and Backbone Treatments of Multiple Myeloma Patients"@en ;
  schema:alternateName "STOMP"@en ;
  schema:description "A phase 1/2 trial of Selinexor, Dexamethasone, Lenalidomide in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02343042/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02343042> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2015-10" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:companies <https://onco.cc/companies/karyopharm/> .